Promising Clinical Trial Results and Strategic Positioning Propel OSE Immunotherapeutics SA to a Buy Rating

OSE Immunotherapeutics SA (6OP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on the stock and has a €14.00 price target.

Sean Lee CFA has given his Buy rating due to a combination of factors related to OSE Immunotherapeutics SA’s promising clinical trial results and strategic positioning. The company’s anti-IL7 receptor antibody, lusvertikimab, has shown significant potential in treating ulcerative colitis (UC), with 91% of patients maintaining responses after six months in the open-label long-term expansion phase of the Phase 2 CotiKis study. These results suggest a durable remission, reinforcing the drug’s potential benefits and supporting further development in Phase 3 studies.
Moreover, the promising outcomes from the expansion phase bode well for lusvertikimab’s potential future approval, especially when compared to recently approved treatments like Eli Lilly’s mirikizumab. Additionally, the return of lusvertikimab’s licensing rights to OSE provides the company with strategic flexibility to seek new partnerships for co-development. The Buy rating is also supported by a risk-adjusted net present value analysis, which underpins the €14 price target, accounting for projected product revenues and financial positioning until 2030.